Might SARS-CoV-2 Have Arisen via Serial Passage through an Animal Host or Cell Culture? : A potential explanation for much of the novel coronavirus' distinctive genome

© 2020 Wiley Periodicals LLC..

Despite claims from prominent scientists that SARS-CoV-2 indubitably emerged naturally, the etiology of this novel coronavirus remains a pressing and open question: Without knowing the true nature of a disease, it is impossible for clinicians to appropriately shape their care, for policy-makers to correctly gauge the nature and extent of the threat, and for the public to appropriately modify their behavior. Unless the intermediate host necessary for completing a natural zoonotic jump is identified, the dual-use gain-of-function research practice of viral serial passage should be considered a viable route by which the novel coronavirus arose. The practice of serial passage mimics a natural zoonotic jump, and offers explanations for SARS-CoV-2's distinctive spike-protein region and its unexpectedly high affinity for angiotensin converting enzyme (ACE2), as well as the notable polybasic furin cleavage site within it. Additional molecular clues raise further questions, all of which warrant full investigation into the novel coronavirus's origins and a re-examination of the risks and rewards of dual-use gain-of-function research.

Errataetall:

CommentIn: Bioessays. 2021 Apr;43(4):e2100017. - PMID 33576073

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:42

Enthalten in:

BioEssays : news and reviews in molecular, cellular and developmental biology - 42(2020), 10 vom: 18. Okt., Seite e2000091

Sprache:

Englisch

Beteiligte Personen:

Sirotkin, Karl [VerfasserIn]
Sirotkin, Dan [VerfasserIn]

Links:

Volltext

Themen:

ACE2 protein, human
Angiotensin-Converting Enzyme 2
COVID-19
Coronavirus
EC 3.4.15.1
EC 3.4.17.23
Gain-of-function
Intermediate host
Journal Article
Pandemic
Peptidyl-Dipeptidase A
SARS-CoV-2
Serial passage
Spike Glycoprotein, Coronavirus
Spike glycoprotein, SARS-CoV
Virology

Anmerkungen:

Date Completed 05.10.2020

Date Revised 16.07.2022

published: Print-Electronic

CommentIn: Bioessays. 2021 Apr;43(4):e2100017. - PMID 33576073

Citation Status MEDLINE

doi:

10.1002/bies.202000091

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM313607559